Navigation Links
What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study
Date:9/13/2008

BOSTON, Sept. 13 /PRNewswire-USNewswire/ -- Cardiovascular disease kills more women each year than all cancers combined. Although this statistic is gaining more recognition among physicians and patients, the unique risk factors and symptoms of female patients make diagnosis and prognosis of women with heart disease particularly challenging.

Data from the WOMEN Study: What is the Optimal Method of Ischemia Evaluation in WomeN presented today at the American Society of Nuclear Cardiology Annual Scientific Session seeks to compare exercise stress testing alone or with myocardial perfusion imaging to determine the best method for detecting heart disease in symptomatic women. The study goal is to determine the best method based upon a 2 year follow-up. Researchers will present baseline data from the study, including demographics, pre-test likelihood of coronary artery disease, and initial test results.

"The strength of this study is the large enrollment and careful follow-up to optimize diagnostic strategies in symptomatic women," said Dr. Gary Heller, who will be presenting data at today's meeting on behalf of the four investigators who initiated the study -- Drs. Gary Heller, Robert Hendel, Jennifer Mieres, and Leslee Shaw. "The goal of the study is to improve outcomes in women with coronary artery disease by earlier and better detection."

During a two-year recruitment period, 826 patients were enrolled from 46 sites. Entry criteria were based on American College of Cardiology guidelines and the ability to exercise as determined by the Duke Activity Status (DASI) questionnaire. Women were randomized to either electrocardiogram exercise tolerance testing (ETT) alone or ETT with Tc-99m tetrofosmin SPECT myocardial perfusion imaging. Ongoing results are monitored by a Data Safety and Monitoring Board with all events adjudicated. Major adverse cardiac events will be evaluated at one and two years.

Dr. Gary Heller will present this study, "What Is the Optimal Method for Ischemia Evaluation in Women: Preliminary Data from the WOMENs Trial" Saturday, September 13, 2008 at 10:50 a.m. in Room 306.

The American Society of Nuclear Cardiology (ASNC) is the leader in education, advocacy, and quality for the field of nuclear cardiology. Serving more than 5,000 individuals in over 50 countries, ASNC is the only professional association dedicated to the dynamic subspecialty of nuclear cardiology.


'/>"/>
SOURCE American Society of Nuclear Cardiology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Genetics Determine Optimal Drug Dose of Common Anticoagulant
2. Endoscopy Identified as Safe and Effective Method in Treating Common Complication of Gastric Bypass Surgery
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
5. Novel PCT Method Unveiled by Pressure BioSciences, Inc. and Collaborators at the Harvard School of Public Health
6. Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials
7. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
8. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
9. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
10. febit and TGen Collaborate to Study New DNA Capture Method
11. Sangart, Inc. Initiates Dosing in Phase II Study of Hemospan(R) in Chronic Critical Limb Ischemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of Jerusalem announced today that it had signed ... BioTheryX, Inc. , developer of novel protein degradation and ... development and commercialization of drug candidates representing first-in-class therapy ... license were not disclosed. The novel technology ...
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Myeloid Leukemia Market ... to their offering.       (Logo: ... Myeloid Leukemia Market and Competitive Landscape Highlights ... Leukemia pipeline products, Acute Myeloid Leukemia epidemiology, ...
(Date:5/3/2016)... 2016 Research and Markets has ... Cell Therapy Market Outlook 2020" report to their ... , ,Recombinant technology has improved significantly in past years ... developed in coming years. Many cancer drugs have been ... therapies are also expected to be developed with its ...
Breaking Medicine Technology:
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... 2016 , ... RowdMap, Inc. co-founder, Joshua Rosenthal, PhD, joins ... Deputy Administrator at Centers for Medicare and Medicaid Services (CMS); Ali Khan, MD, ... Officer at Health Care Service Corporation (Blue Cross and Blue Shield of Illinois, ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... This weekend, from Friday, May 6 - ... on steep California terrain at the first Team Semper Fi Mountain Bike Camp, hosted in ... will be mountain bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):